Autologous stem cell transplantation for multiple myeloma in the era of new drugs
10.3969/j.issn.1000-8179.20142171
- VernacularTitle:新药时代自体造血干细胞移植在多发性骨髓瘤中的应用前景
- Author:
Jian HOU
;
Jianling FAN
- Publication Type:Journal Article
- Keywords:
autologous stem-cell transplantation;
multiple myeloma;
novel drug;
bortezomib;
thalidomide;
lenalidomide
- From:
Chinese Journal of Clinical Oncology
2015;(1):8-12
- CountryChina
- Language:Chinese
-
Abstract:
Autologous stem cell transplantation (ASCT) is the standard frontline therapy for newly diagnosed multiple myeloma (MM) in patients younger than 65 years in the era of conventional chemotherapy. The use of novel drug-based chemotherapy in the in-duction, consolidation, and maintenance phases of chemotherapy has significantly improved the response rates of patients. Thus, wheth-er or not ASCT is still necessary in the era of new drugs has become controversial. Currently available data supported that ASCT should be the frontline therapy for qualified newly diagnosed MM patients and that new drugs may be applied before and after ASCT to further improve the response rate and prolong the progression-free survival of patients. Further prospective clinical trials should be conducted to clarify the role of ASCT in MM and optimize the treatment strategies involving ASCT in the era of new drugsto cure myeiona.
